[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-426206-105":59,"doc-detail-426206-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","continuation-of-glp-1-receptor-agonists-during-post-acute-skilled-nursing-facility-stays-and-30-day-outcomes","Continuation of GLP-1 Receptor Agonists During Post-Acute Skilled Nursing Facility Stays and 30-Day Outcomes","","Continuity of GLP-1 receptor agonists (GLP-1RAs) during Medicare Part A skilled-nursing facility (SNF) stays is unknown. A retrospective cohort of 7,037 older adults was assembled using national Long-Term Care Data Cooperative EHR linked to Medicare claims across 2,500+ SNFs. Exposure was percent days covered in SNF stay (discontinuers 0%, partial >0–\u003C90%, complete ≥90%) and propensity weighting balanced major demographics, frailty, diagnoses, utilization, facility factors, metabolic and cognition measures. Thirty-day composite death or cardiovascular hospitalization was lower with partial (10.66% vs 8.26%) and complete (10.66% vs 8.59%); hazard ratios favored continuation. Safety events for ketoacidosis or glucose extremes were also reduced with continuation, supporting not stopping GLP-1RAs during short SNF stays.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/continuation-of-glp-1-receptor-agonists-during-post-acute-skilled-nursing-facility-stays-and-30-day-outcomes/426206/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/continuation-of-glp-1-receptor-agonists-during-post-acute-skilled-nursing-facility-stays-and-30-day-outcomes/426206.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-19","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was GLP-1RA continuity measured during SNF stays?","Question",{"text":112,"@type":113},"Continuity was defined as the percent days covered by GLP-1RA during the SNF stay, grouped as discontinuers (0%), partial continuers (>0–\u003C90%), and complete continuers (≥90%).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What outcomes were evaluated over 30 days?",{"text":117,"@type":113},"The primary endpoint was a 30-day composite of death or cardiovascular hospitalization, including heart failure, acute myocardial infarction, or stroke. The safety endpoint was 30-day hospitalization for diabetic ketoacidosis or hypo/hyperglycemia.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about stopping GLP-1RAs during SNF stays?",{"text":121,"@type":113},"Partial or complete continuation was associated with lower 30-day mortality/CV risk than discontinuation, arguing against stopping during short SNF stays.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},426206,1790767934,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","SESSION 9085 (PAPER)   \nLATE BREAKING: CLINICAL PRACTICE  \nINNOVATIONS II  \nAbstract citation ID: igaf122.4331  \nCONTINUATION OF GLP-1 RECEPTOR AGONISTS DURING POST-ACUTE SKILLED NURSING FACILITY STAYS AND 30-DAY OUTCOMES  \nChan Mi Park1, Eunji G. Kim2, Lan Luo2, Xiecheng Chen3, Dae Hyun Kim4, and Ellen McCarthy4, 1. Hebrew SeniorLife, Harvard Medical school, Boston, Massachusetts, United States, 2. Marcus Institute for Aging Research, Boston, Massachusetts, United States, 3. Hebrew Rehabilitation Center, Roslindale, Massachusetts, United States, 4. Hebrew SeniorLife, Boston, Massachusetts, United States  \nIn Medicare Part A– skilled-nursing facility (SNF) care—where facilities receive a predetermined, fixed amount per day—continuity of GLP-1 receptor agonists (GLP-1RAs) is unknown. Using the Long-Term Care Data Cooperative, a national provider-led EHR data linked to Medicare claims (>2,500 SNFs), we assembled a retrospective cohort of 7,037 older adults who received a GLP-1RA for ≥90 days before SNF admission. Exposure was percent days covered during the SNF stay: discontinuers (0%), partial continuers (>0–\u003C 90%), and complete continuers (≥90%) . Propensity scores with overlap weighting balanced demographics, frailty, primary diagnosis of hospitalization, healthcare utilization, facility ownership, glucose and kidney functions, cognition/ADLs, BMI, chronic conditions, and concomitant medications across three exposures (SMD \u003C 0.10) . After weighting, sample sizes were: discontinuers n = 612.6, partial n = 615.2, complete n = 612.6. Weighted baseline characteristics were similar: mean age 74.8 years; 38% male; race/eth∼nicity 79% non∼ -Hispanic White; diabetes∼ treatment profile 44%  \ninsulin, 33–34% metformin, and 37–38% other second-line therapy at baseline. The primary endpoint was a 30-day composite of death or cardiovascular hospitalization (heart failure, acute myocardial infarction, stroke); the safety endpoint was 30-day hospitalization for diabetic ketoacidosis or hypo/hyperglycemia. 30-day cumulative incidence for the composite was 10.66%(discontinuers) vs 8.26%(partial) vs 8.59%(complete) . The hazard ratio for the composite was 0.77 (95% CI, 0.63–0.93) for partial and 0.80 (95% CI, 0.63–1.00) for complete compared to the discontinuers. Safety events were lower with continuation (1.19% vs 0.69% vs 0.63%) . GLP-1RA continuation—partial or complete—was associated with lower 30-day mortality/CV risk than discontinuation, arguing against stopping during short SNF stays.","cbCaiq23Exxootlj","https://ap.wps.com/l/cbCaiq23Exxootlj","pdf",1155064,"English","# Abstract\n## Study design and cohort\n## Exposure definitions and propensity weighting\n## Primary and safety endpoints","[{\"question\":\"How was GLP-1RA continuity measured during SNF stays?\",\"answer\":\"Continuity was defined as the percent days covered by GLP-1RA during the SNF stay, grouped as discontinuers (0%), partial continuers (\\u003e0–\\u003c90%), and complete continuers (≥90%).\"},{\"question\":\"What outcomes were evaluated over 30 days?\",\"answer\":\"The primary endpoint was a 30-day composite of death or cardiovascular hospitalization, including heart failure, acute myocardial infarction, or stroke. The safety endpoint was 30-day hospitalization for diabetic ketoacidosis or hypo/hyperglycemia.\"},{\"question\":\"What did the study find about stopping GLP-1RAs during SNF stays?\",\"answer\":\"Partial or complete continuation was associated with lower 30-day mortality/CV risk than discontinuation, arguing against stopping during short SNF stays.\"}]","Continuation of GLP-1 Receptor Agonists During Post-Acute Skilled Nursing Facility Stays and 30-Day Outcomes | PDF",1790639738]